Results 131 to 140 of about 121,048 (155)

Integrating vaginal laser therapy into multidisciplinary management of bladder pain syndrome and vulvodynia. [PDF]

BMC Urol
Okui N.
europepmc   +1 more source

Long-term effects of ospemifene on densitometric and bone metabolism biomarkers in postmenopausal women reporting Vulvar and Vaginal Atrophy (VVA). [PDF]

BMC Womens Health
Maffei S, Formica A, Corsini D, Franchini M.   +3 more
europepmc   +1 more source

Predicting phototherapy efficacy in vulvar lichen sclerosus using high-frequency ultrasound combined with superb microvascular imaging. [PDF]

Front Med (Lausanne)
Liu Y, Lu Y, Guo Y, Li C, Shen K.
europepmc   +1 more source

Molecular mechanisms and therapeutic perspectives in vulvodynia: From current evidence to future investigations. [PDF]

Cell Rep Med
Albano A, Brasi L, Loperfido F, Griffante G, Cianci MA, Donati G, Proserpio V.   +6 more
europepmc   +1 more source

A Randomized Controlled Pilot Trial Evaluating the Efficacy of Intravaginal and Extravaginal K-Laser Therapy as a Personalized Non-Hormonal Treatment for Genitourinary Syndrome of Menopause. [PDF]

J Pers Med
Martín-Valero R, Ruiz-Moreno AM, Gallardo-García PJ, Martínez Colmena MD, Muñoz Pagan C, González-Rojas P, Ortega Quiñonero P.   +6 more
europepmc   +1 more source

Comparison of the efficacy and adverse reactions of ATP combined with microwave therapy and traditional glucocorticoid therapy for lichen sclerosus in women. [PDF]

Medicine (Baltimore)
Pei X, Wang M, Lu D, Wang H, Jia Y.
europepmc   +1 more source

Stratifying the risk of anal high-grade squamous intraepithelial lesion among immunosuppressed women with genital HPV. [PDF]

Front Immunol
Matas I, Pifarré M, Torné A, Saco A, Darecka K, Guerra E, Martí C, Bruch J, Cardiel A, Rakislova N, Marimon L, Mayordomo-Bofill I, Victoria I, Alós S, Fusté P, Ordi J, Del Pino M.   +16 more
europepmc   +1 more source

Effect of ospemifene on moderate or severe symptoms of vulvar and vaginal atrophy [PDF]

Climacteric, 2016
Objectives To determine whether assessment of all moderate-to-severe symptoms at baseline gives a more accurate evaluation of the treatment effect of ospemifene in vulvovaginal atrophy (VVA) than the most bothersome symptom (MBS) approach.
Rossella E Nappi, Camil Castelo-Branco, T J de Villiers   +2 more
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Vulvar and vaginal atrophy in four European countries: evidence from the European REVIVE Survey

Climacteric, 2016
Nick Panay, Rossella E Nappi, Santiago Palacios   +2 more
exaly  

The clinical relevance of the effect of ospemifene on symptoms of vulvar and vaginal atrophy

Climacteric, 2015
Nick Panay, Rossella E Nappi, Camil Castelo-Branco   +2 more
exaly